Literature DB >> 18204919

Contribution of relapses to disability in multiple sclerosis.

Claire Hirst1, Gillian Ingram, Owen Pearson, Trevor Pickersgill, Neil Scolding, Neil Robertson.   

Abstract

The impact of relapses on long-term disability in multiple sclerosis remains unclear; however some evidence suggests that relapses play an important role in determining subsequent prognosis. We report on outcome, prognostic factors for recovery and the contribution of relapses to the accumulation of fixed disability in a large series of patients with documented relapses. Two hundred and seventy-nine relapses in 182 patients were assessed before, during and after relapse by expanded disability status scale and data analysed to assess degree of recovery. Factors affecting outcome were considered including sex, age and site of relapse. Mean EDSS prior to relapse was 3.73, during relapse 5.18 and post relapse 4.23. Mean interval to post relapse assessment was 127 days post relapse. Mean residual change in EDSS score (pre to post relapse) was 0.50 points. Overall 49.4 % of patients had a residual increase in disability post relapse of at least 0.5 EDSS points and 32.7 % had an increase of at least 1 point. No significant difference was observed in mean residual EDSS for sex, site of relapse or age at relapse or in the proportion of patients with a residual increase in disability of > or = 1 EDSS point post relapse. 14.4 % of patients had no increase in EDSS score during relapse compared to pre relapse. These results suggest that acute relapses are commonly associated with an objective worsening of disability in the majority of patients with MS and that recovery is incomplete in approximately half and not influenced by gender, age or site of lesion. Therapies which reduce relapse frequency and/or severity might therefore be expected to slow or prevent worsening of disability if initiated prior to the onset of more permanent damage.

Entities:  

Mesh:

Year:  2008        PMID: 18204919     DOI: 10.1007/s00415-008-0743-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  30 in total

1.  PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS.

Authors:  G A SCHUMACHER; G BEEBE; R F KIBLER; L T KURLAND; J F KURTZKE; F MCDOWELL; B NAGLER; W A SIBLEY; W W TOURTELLOTTE; T L WILLMON
Journal:  Ann N Y Acad Sci       Date:  1965-03-31       Impact factor: 5.691

2.  Interrater variability with the Expanded Disability Status Scale (EDSS) and Functional Systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group.

Authors:  J H Noseworthy; M K Vandervoort; C J Wong; G C Ebers
Journal:  Neurology       Date:  1990-06       Impact factor: 9.910

3.  The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-12       Impact factor: 13.501

4.  Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis.

Authors:  M P Amato; L Fratiglioni; C Groppi; G Siracusa; L Amaducci
Journal:  Arch Neurol       Date:  1988-07

Review 5.  Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences.

Authors:  C Bjartmar; B D Trapp
Journal:  Curr Opin Neurol       Date:  2001-06       Impact factor: 5.710

6.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

7.  High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.

Authors:  L Durelli; D Cocito; A Riccio; C Barile; B Bergamasco; G F Baggio; F Perla; M Delsedime; G Gusmaroli; L Bergamini
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

8.  Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.

Authors:  P W O'Connor; A Goodman; A J Willmer-Hulme; M A Libonati; L Metz; R S Murray; W A Sheremata; T L Vollmer; L A Stone
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

9.  Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG).

Authors:  O Kantarci; A Siva; M Eraksoy; R Karabudak; N Sütlaş; J Ağaoğlu; F Turan; M Ozmenoğlu; E Toğrul; M Demirkiran
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

10.  Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.

Authors:  W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

View more
  32 in total

Review 1.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

2.  Impact of multiple sclerosis relapses on progression diminishes with time.

Authors:  H Tremlett; M Yousefi; V Devonshire; P Rieckmann; Y Zhao
Journal:  Neurology       Date:  2009-11-04       Impact factor: 9.910

3.  Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective.

Authors:  Amy Perrin Ross; June Halper; Colleen J Harris
Journal:  Int J MS Care       Date:  2012

4.  Towards the implementation of 'no evidence of disease activity' in multiple sclerosis treatment: the multiple sclerosis decision model.

Authors:  Martin Stangel; Iris Katharina Penner; Boris A Kallmann; Carsten Lukas; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2015-01       Impact factor: 6.570

5.  Burden of a multiple sclerosis relapse: the patient's perspective.

Authors:  Merrikay Oleen-Burkey; Jane Castelli-Haley; Maureen J Lage; Kenneth P Johnson
Journal:  Patient       Date:  2012       Impact factor: 3.883

6.  Reducing costs while enhancing quality of care in MS.

Authors:  Ilya Kister; John R Corboy
Journal:  Neurology       Date:  2016-09-02       Impact factor: 9.910

Review 7.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

8.  Validation of a new quality of life scale related to multiple sclerosis and relapses.

Authors:  Antoine Baroin; Gilles Chopard; Gaye Siliman; Clément Michoudet; Aurore Vivot; Chrystelle Vidal; Hassna Mokadym; Annick Lavier; Eric Berger; Lucien Rumbach; Nathalie Rude
Journal:  Qual Life Res       Date:  2012-12-18       Impact factor: 4.147

Review 9.  Clinical markers of therapeutic response to disease modifying drugs.

Authors:  Carlo Pozzilli; Luca Prosperini
Journal:  Neurol Sci       Date:  2008-09       Impact factor: 3.307

10.  Clinical predictors of early second event in patients with clinically isolated syndrome.

Authors:  Ellen M Mowry; Mila Pesic; Barbara Grimes; Serina R Deen; Peter Bacchetti; Emmanuelle Waubant
Journal:  J Neurol       Date:  2009-03-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.